Live moderated video webcast with members of
CNS Pharmacetucals management and Key Opinion Leader, Professor
Michael Weller, MD, on Tuesday, April 4th at 3:00 PM ET
HOUSTON, March 29,
2023 /PRNewswire/ -- CNS Pharmaceuticals,
Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a
biopharmaceutical company specializing in the development of novel
treatments for primary and metastatic cancers in the brain and
central nervous system, today announced that it will present at the
Virtual Investor GBM Spotlight Event on Tuesday, April 4, 2023 at 3:00 PM ET.
As part of the event, John
Climaco, Chief Executive Officer of CNS Pharmaceuticals will
be joined by Key Opinion Leader Professor Michael Weller, MD, to discuss GBM, the unmet
need and the work CNS Pharmaceuticals is doing to advance Berubicin
for the treatment of recurrent glioblastoma multiforme (GBM), one
of the most aggressive types of brain cancer.
Dr. Weller is a leading Neuro-oncologist who currently serves as
the Chairman of the Department of Neurology at the University
Hospital in Zurich, Switzerland
and as the National Coordinating Investigator for CNS
Pharmaceuticals' potentially pivotal study. Over the course of his
career, Dr. Weller has focused his practice and research on the
diagnosis and treatment of brain tumors, including immunotherapy,
and has been involved in major practice-changing clinical trials
including the registration trial for temozolomide in glioblastoma.
He has received several awards in recognition of his important
contributions to cancer research, including the German Cancer Award in 2007. He has co-authored
more than 550 original publications in peer-reviewed journals and
is on the Executive Board of the European Association for
Neuro-Oncology (EANO), serving as President of EANO from
2014–2016.
A live video webcast of the event will be available on the
Events page of the Investors section of the Company's
website (cnspharma.com). A webcast replay will be available two
hours following the live presentation and will be accessible for 90
days.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company
developing a pipeline of anti-cancer drug candidates for the
treatment of primary and metastatic cancers of the brain and
central nervous system. The Company's lead drug candidate,
Berubicin, is a novel anthracycline and the first anthracycline to
appear to cross the blood-brain barrier. Berubicin is currently in
development for the treatment of a number of serious brain and CNS
oncology indications including glioblastoma multiforme (GBM), an
aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com, and
connect with the Company on Twitter, Facebook, and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-virtual-investor-gbm-spotlight-event-301784462.html
SOURCE CNS Pharmaceuticals, Inc.